相关实验视频

Updated: Jun 19, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

引入一根伊索普雷纳林释放导线:关于其设计的报告和剂量决定试点研究的结果

Jeff John^1,2, Mark Wellman¹, Charné Dixon³

¹Division of Urology, Department of Surgery, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.

Journal of endourology

|March 12, 2024

概括

一种新型的导线释放异上腺素,在逆行性内手术 (RIRS) 期间安全降低内压力 (IRP). 这种创新的设备显示了改善外科手术安全性和结果的希望.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
手术创新在外科创新.
医疗器械开发医疗器械开发

背景情况:

逆行性内外科手术 (RIRS) 的并发症通常与内压力升高 (IRP) 有关.
在RIRS手术中,管理IRP对于患者安全和手术成功至关重要.

研究的目的:

在RIRS期间设计和评估一种新型异上腺素排泄导线 (IsoWire) 以减少IRP.
评估IsoWire在体外和动物研究中的安全性和有效性.

主要方法:

开发了具有尼醇核心,不钢线圈和充满异二烯的水凝涂层的IsoWire.
*体外*释放药物的研究,以确定异上腺素化特征.
猪模型研究用标准和IsoWire导线测量IRP,心率 (HR) 和平均动脉压 (MAP).

主要成果:

实验室研究显示,在最初的4分钟内,异上腺素的释放速度快,指数级.
在猪身上进行的研究表明,在特定的异上腺素剂量 (5和7.5μg) 中,IsoWire显著降低了IRP (高达21.3%).
使用IsoWire剂量为5和7.5μg并没有显著改变HR或MAP,这表明它具有安全的生理特征.

结论:

释放5和7.5微克异上腺素的IsoWire在模拟RIRS期间安全有效地降低了IRP.
需要进一步的研究来探索IsoWire在促进尿管接入插入和促进无RIRS方面的潜力.

关键词:

灵活的尿道透视镜.内压力内压力这种药物是异二烯林.激光石化三维精神治疗逆行性内外科手术逆行性内外科尿病是一种尿病.

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

相关概念视频

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...